Key features and details
- Sensitivity: 30 ng/ml
- Range: 30 ng/ml - 1000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Product nameBevacizumab ELISA Kit
See all Bevacizumab kits
Intra-assay Sample n Mean SD CV% Overall < 30% Inter-assay Sample n Mean SD CV% Overall < 30%
Sample typeSerum, Plasma
Range30 ng/ml - 1000 ng/ml
Sample specific recovery Sample type Average % Range Serum 70% - 130%
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Note: Bevacizumab ELISA kit ab237642 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Bevacizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Storage instructionsStore at +4°C. Please refer to protocols.
Components 96 tests Assay Buffer 2 x 50ml Bevacizumab Standard S1 (100 µg/mL) 1 x 300µl Bevacizumab Standard S2 (30 µg/mL) 1 x 300µl Bevacizumab Standard S3 (10 µg/mL) 1 x 300µl Bevacizumab Standard S4 (3 µg/mL) 1 x 300µl Bevacizumab Standard S5 (0 µg/mL) 1 x 300µl Bevacizumab Standard S6 (High Control) 1 x 300µl Bevacizumab Standard S7 (Low Control) 1 x 300µl HRP-conjugate Probe 1 x 12ml Micro ELISA Plate 1 unit Plate sealers 2 units Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash Buffer (20X) 1 x 50ml
RelevanceBevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.
ab237642 has not yet been referenced specifically in any publications.